TriangleHEALTH PROFESSIONAL · SOURCE READING
Preoperative Imatinib
Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 13, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Key References for Treatment of GISTs
8 to 12 weeks
Eisenberg BL, Harris J, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99 (1): 42-7, 2009. [PUBMED Abstract]Cited in:
Source links and citations
Eisenberg BL, Harris J, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99 (1): 42-7, 2009. [PUBMED Abstract]Cited in:
Treatment of Unresectable Primary GISTs
Source links and citations
6 to 9 months
Kurokawa Y, Yang HK, Cho H, et al.: Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117 (1): 25-32, 2017. [PUBMED Abstract]Cited in:
Source links and citations
Kurokawa Y, Yang HK, Cho H, et al.: Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117 (1): 25-32, 2017. [PUBMED Abstract]Cited in:
Treatment of Unresectable Primary GISTs
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice